Hughes-Stovin Syndrome is a very rare clinical entity characterized by pulmonary artery aneurysms and deep vein thrombosis (DVT). Here we report the case of a 53-year-old man, admitted to Sultan Qaboos University Hospital, Muscat, Oman, with bilateral pulmonary artery aneurysms and lower-limb DVT who developed massive hemoptysis. He was managed successfully with high-dose steroids in combination with cyclophosphamide.
Khalfan Al-Zeedy, et al.

Oxygen for a couple of days, initially at 10L/minute through a non-rebreather mask. A bedside echocardiogram did not show any evidence of intracardiac thrombi or pulmonary hypertension. The patient had massive hemoptysis, features of thrombus in the pulmonary artery, and DVT. This raised the question of prescribing anticoagulants. However, anticoagulants were not given due to the known risk of a fatal hemorrhage occurring from the pulmonary artery aneurysms. The patient was then prescribed oral prednisolone at 50mg daily for one week, followed by 40mg daily for two weeks, which was later tapered to a maintenance dose. Monthly cyclophosphamide injections were continued for a year. A chest radiograph after three months showed almost complete resolution of the hilar shadows [Figure 3]. At two-year follow-up, the patient was on a daily dose of prednisolone 5mg and mycophenolate 5mg, he did not redevelop hemoptysis and had remained relatively asymptomatic.

**DISCUSSION**

HSS is a very rare clinical condition which was first described by two British physicians, Hughes and Stovin, in 1959. It usually affects young men aged between 12–40 years. The characteristics of HSS are the formation of DVT and pulmonary artery aneurysms. The initial presentation is usually non-specific and patients may present with coughing, shortness of breath, fever, or chest pain. Hemoptysis can either arise later or be observed at the initial presentation. The aneurysms usually involve the pulmonary and/or the bronchial arteries, although the systemic circulation can be affected too. They can present with vascular thromboembolism, arterial aneurysms, arterial and venous occlusions, non-specific vasculitis and even thrombophlebitis. The most serious complication of HSS is the possibility of developing a massive and potentially fatal hemorrhage.

The exact etiology of HSS remains unclear. While infection and sepsis were considered possible causes of this syndrome, the absence of any positive cultures and the lack of patient response to antibiotics does not support this hypothesis. The current consensus is that HSS results from vasculitis, similar to the vasculitis seen in Behçet’s disease. In fact, some consider HSS an "incomplete" form of Behçet’s disease since the same combination of
multiple pulmonary aneurysms and peripheral vein thrombosis have been described in Behçet’s disease. However, the typical features of Behçet’s disease such as orogential ulcers, skin lesions, iritis, or arthritis are missing in most HSS cases. The exact pathogenesis of pulmonary artery aneurysms is not well established, although they have been attributed to a weakness of the vessel wall due to inflammation. Hughes and Stovin suggested that the aneurysms develop due to the degenerative changes in the walls of the bronchial arteries, with subsequent changes in the vasa vasorum of the pulmonary artery. This theory was supported by findings of dilated and distorted bronchial arteries and convoluted small branches in digital subtraction angiograms. The pulmonary artery thrombosis develops in situ due to the inflammation of the arterial wall and not as thromboembolism developing from peripheral vein thrombosis. In fact, pulmonary embolism is rare in patients with Behçet’s disease and DVT. This is possibly due to the fact that the thrombi in these patients adhere to the walls of the veins.

No standardized guidelines exist for the treatment of HSS and immunosuppressant drugs remain the predominant first-line therapy. This usually involves a combination of steroids and cytotoxic agents, the most commonly used being cyclophosphamide. Anticoagulants and thrombolytic agents are generally contraindicated in patients with HSS due to the increased risk of fatal hemorrhage from pulmonary aneurysms. Therefore, the physician is often confronted with a challenge regarding optimal patient management particularly when an embolic state is noted in patients with a pro-thrombotic tendency. Some of these patients may even have hemoptysis upon initial presentation. Hemoptysis can occur due to the rupture of an aneurysm, acute vasculitis, or due to rupture of the angiodysplastic bronchial arteries. Anticoagulants have been used judiciously in patients with intracardiac thrombi or embolisms in the main pulmonary artery and in those with hemodynamic instability. Some physicians have used anticoagulants in cases of unilateral single pulmonary aneurysms that were surgically resected, or after adequate immunosuppressive treatment. However, the need for anticoagulation is not always clear as the risk of pulmonary embolism is very low and these patients may still develop thrombosis despite adequate anticoagulation.

Anticoagulation should be considered with extreme caution and only in clinical situations where the benefits clearly outweigh the risks. More studies are required to reach a consensus on this issue.

Surgical resection of the affected lung can be considered if the aneurysms are at a high risk of rupturing and/or are localized to one segment or one lung. However, surgical interventions usually carry a higher risk and the pulmonary aneurysms often tend to be both bilateral and multiple. Embolization can also be considered in patients in danger of rupturing or in cases of fatal hemoptysis. In our patient, the massive hemoptysis was managed successfully with a combination of steroids and cyclophosphamide. This case highlights the effectiveness of immunosuppressant treatment in the management of massive hemoptysis in a patient with HSS.

CONCLUSION

HSS is a very rare clinical disorder characterized by pulmonary artery aneurysms and DVT, which resembles Behçet’s disease in many ways. Management of patients with HSS who develop massive hemoptysis is often tricky and requires supportive care along with immunosuppressive treatment. In our case the patient was managed successfully using a combination of steroids and cyclophosphamide.

Disclosure

The authors declared no conflict of interest.

REFERENCES


